Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BMS 182874

Known as: BMS-182874 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats.
Vascular superoxide anion (O(2)(*-)) levels are increased in DOCA-salt hypertensive rats. We hypothesized that the endothelin (ET… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2003
Highly Cited
2003
Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.
OBJECTIVES We investigated if endothelin (ET)-1 and the renin-angiotensin-aldosterone system play a role in cardiac fibrosis… Expand
2000
2000
Role of NO and cytochrome P-450-derived eicosanoids in ET-1-induced changes in intrarenal hemodynamics in rats.
Endothelin-1 (ET-1) produces potent renal effects that we have previously shown to be dependent on cytochrome P-450 (CYP450… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
1998
1998
The ETA receptor antagonist, BMS-182874, reduces acute hypoxic pulmonary hypertension in pigs in vivo.
OBJECTIVE Elevated levels of the potent vasoactive peptide endothelin (ET), have been found in pathophysiological conditions… Expand
  • table 1
  • table 2
  • figure 2
Highly Cited
1996
Highly Cited
1996
Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation.
BACKGROUND Studies in experimental models of chronic renal failure suggest an important role for the endothelin system in the… Expand
1996
1996
Mutational analysis of the endothelin type A receptor (ETA): interactions and model of selective ETA antagonist BMS-182874 with putative ETA receptor binding cavity.
Endothelin (ET) receptor antagonism is a potential therapeutic intervention in the treatment of vascular diseases. To elucidate… Expand
1995
1995
BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist.
BMS-182874 [5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalene sulfonamide] is a recently discovered, low molecular… Expand
Highly Cited
1995
Highly Cited
1995
Orally Active Endothelin Receptor Antagonist BMS‐182874 Suppresses Neointimal Development in Balloon‐Injured Rat Carotid Arteries
Vascular smooth muscle cell (SMC) proliferation is an important component in the development of restenosis. Because endothelin… Expand
Highly Cited
1995
Highly Cited
1995
Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol.
Recent studies suggest that endothelin and its receptors may be involved in atherogenesis. To test this hypothesis, cholesterol… Expand
Highly Cited
1994
Highly Cited
1994
Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity.
The molecular basis for endothelin (ET) isopeptide selectivity between ETA and ETB receptors was studied by examining ligand… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE